Gujarat Kidney and Super Speciality's shares concluded their debut trading session down 8% from their issue price, despite listing at a 5.2% premium. The company's IPO, priced between 108-114, aimed to raise 251 crore for expansion and debt repayment. This listing occurs amidst a strong year for India's primary markets, with 2025 seeing the highest number of IPOs in 25 years, demonstrating resilience despite secondary market volatility.